As of 6 Nov 2026, Krebs Biochemicals and Industries is loss-making on a trailing 12-month basis, with a net loss of ₹13 Cr, so it has no P/E ratio. The share price is ₹57.50, 25% below its 52-week high. Sales fell 23% a year over 3 years. Its net worth is negative, as liabilities exceed assets, and borrowings are ₹227 Cr. It is a small-cap company with a market cap of ₹124 Cr, ranked 113th of 154 Drug Manufacturers (Specialty & Generic) companies by market cap; the shares fell 17% over the past year.
- ₹57.80
- ₹58.78
- ₹56.26
- ₹57.86
- 2.4K
Health check
- ReturnsBehind
−16.9% over a year, better than 0 of 7 peers.
- Price tagNegative equity
Book value is below zero, so P/E and P/B mislead here.
- GrowthShrinking
Sales −23.1% a year over 3 years.
- ProfitabilityDistorted
With negative net worth, return ratios are meaningless.
- Balance sheetStretched
Negative net worth: liabilities exceed assets.
- Red flags3 to check
Loss-making over the last twelve months.
Small cap
Moves with the market
Key metrics
- Market cap
- ₹124 Cr
- Small cap
- P/E
- n/a
- Industry 28.7
- Price to book
- −0.73
- Peers 4.99
- Dividend yield
- 0.00%
- ROE
- n/a
- Peers 14.7%
- ROCE
- −19.6%
- Peers 17.9%
- Debt to equity
- n/a
- Debt ₹227 Cr
- EPS (TTM)
- −₹6.20
- Face value ₹10
- OPM (TTM)
- −6.2%
- Net margin −49.7%
- Sales growth
- +38.9%
- Latest quarter vs a year ago
- Profit growth
- n/a
- Year-ago quarter not reported
- Price to sales
- 4.62
- EV/EBITDA 7062.9
Strengths and risks
Strengths
- Quarterly sales up 38.9% on a year ago.
Risks to check
- Loss-making over the last twelve months.
- Negative net worth: liabilities exceed assets.
- Interest coverage of only −0.2×.
About Krebs Biochemicals and Industries
Krebs Biochemicals & Industries Limited engages in the manufacture of active pharmaceutical ingredients in India. It offers androstenedione for steroid intermediate indications, as well as lovastatin and simvastatin for anti-cholesterol applications. The company also develops amlodipine and telmisartan for anti-hypertension; cetirizine for antihistamine; orlistat for anti-obesity; serratiopeptidase for anti-inflammatory; and phenylephrine for cold and…
- Headquarters
- Visakhapatnam
- Employees
- 142
- Sector
- Healthcare
- ISIN
- INE268B01013
- Website
- krebsbiochem.com
Price range
- Avg volume (3M)
- 28.2K
- 1-year return
- minus 16.9%
- From 52-week high
- minus 25.2%
Peers · Drug Manufacturers - Specialty & Generic
| Company | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMASun Pharmaceutical Industries | 1,860.00 | plus 1.69% | 4,46,276 | 40.7 | 4.99 | 17.9% | 13.1% | 28.2% | 10.4% | 10.6% | 0.87% | plus 8.2% |
| DIVISLABDivi's Laboratories | 10,320.50 | plus 1.78% | 2,73,977 | 93.6 | 16.35 | 19.0% | 16.2% | 34.9% | 11.0% | 12.1% | 0.30% | plus 49.0% |
| TORNTPHARMTorrent Pharmaceuticals | 4,750.00 | plus 0.85% | 1,80,675 | 80.2 | 9.83 | 9.1% | 15.7% | 33.7% | 13.3% | 20.2% | 0.81% | plus 31.7% |
| LAURUSLABSLaurus Labs | 2,340.00 | minus 0.26% | 1,26,433 | 94.4 | 20.86 | 19.5% | 24.0% | 30.4% | 3.8% | 4.0% | 0.09% | plus 138.6% |
| ZYDUSLIFEZydus Lifesciences | 1,197.90 | plus 0.41% | 1,19,491 | 28.6 | 4.29 | 19.0% | 14.7% | 26.2% | 16.5% | 37.0% | 0.08% | plus 22.8% |
| DRREDDYDr. Reddy's Laboratories | 1,373.00 | plus 0.51% | 1,14,462 | 40.9 | 2.96 | 14.2% | 7.3% | 15.9% | 11.0% | −1.7% | 0.59% | plus 13.8% |
| CIPLACipla | 1,411.00 | plus 0.49% | 1,13,993 | 39.4 | 3.22 | 14.9% | 8.3% | 17.3% | 7.2% | 11.5% | 0.93% | minus 6.6% |
| KREBSBIOKrebs Biochemicals and Industries | 57.50 | minus 0.62% | 124 | – | −0.73 | −19.6% | – | −10.0% | −23.1% | – | 0.00% | minus 16.9% |
| Median of 7 peers | – | 0.51% | 1,26,433 | 40.9 | 4.99 | 17.9% | 14.7% | 28.2% | 11.0% | 11.5% | 0.59% | 22.8% |
Quarterly results
| ₹ Cr | Sep 25 | Dec 25 | Mar 26 | Jun 26 | Sep 26 |
|---|---|---|---|---|---|
| 4.2 | 7.3 | 6.8 | 7 | 5.8 | |
| 7 | 7 | 7.7 | 6.2 | 7.7 | |
| −2.8 | 0.3 | −0.9 | 0.8 | −1.9 | |
| −67.0% | 4.1% | −12.7% | 11.8% | −33.3% | |
| 0 | 0 | 2 | 0.2 | 0 | |
| 1.7 | 1.8 | 1.9 | 1.9 | 1.9 | |
| 1.6 | 1.6 | 1.6 | 1.6 | 1.6 | |
| −6.1 | −3.1 | −2.3 | −2.5 | −5.4 | |
| −6.1 | −3.1 | −2.3 | −2.5 | −5.4 | |
| -2.85 | -1.45 | -1.09 | -1.15 | -2.50 |
Profit & loss
- Sales CAGR 3Y
- −23.1%
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| 52.1 | 50.4 | 43.3 | 23.7 | |
| – | minus 3.3% | minus 14.1% | minus 45.2% | |
| 67.5 | 59.1 | 57.9 | 25.2 | |
| −15.4 | −8.7 | −14.6 | −1.5 | |
| −29.5% | −17.3% | −33.7% | −6.2% | |
| 0.2 | 0.5 | 0.2 | 0.1 | |
| 3 | 4.7 | 5.9 | 7.1 | |
| 6.6 | 6.8 | 6.7 | 6.4 | |
| – | – | 0.1 | −2.1 | |
| −24.7 | −19.7 | −26.9 | −16.9 | |
| – | – | −0.1% | – | |
| −24.7 | −19.7 | −26.9 | −16.9 | |
| -11.30 | -9.15 | -12.49 | -7.85 |
Forecast
Balance sheet
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| 21.6 | 21.6 | 21.6 | 21.6 | |
| −121 | −141 | −168 | −184 | |
| 228 | 239 | 212 | 270 | |
| 46.1 | 58.7 | 103 | 56.2 | |
| 175 | 178 | 169 | 163 | |
| 149 | 150 | 146 | 143 | |
| 2.6 | 0.4 | 1.2 | 1.9 | |
| 2.4 | 2.5 | 2.9 | 2.7 | |
| 0 | 0.1 | 0.3 | 0 | |
| 21 | 25.4 | 18.1 | 15.4 | |
| 175 | 178 | 169 | 163 |
Cash flow
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| −24.7 | 2.4 | −7.9 | −1.9 | |
| −12.6 | −7.8 | −5 | −3.6 | |
| 37.3 | 5.5 | 12.9 | 5.5 | |
| −0 | 0.1 | 0 | −0 | |
| −10.9 | −9.4 | −3.6 | −3.2 | |
| −35.6 | −7.1 | −11.5 | −5.1 |
Shareholding pattern
- Promoters72.74%
- Public27.26%
| Quarter | Split | Promoters | Public | Promoter change |
|---|---|---|---|---|
| 30 Sep 2026 | 72.74% | 27.26% | 0.00 | |
| 30 Jun 2026 | 72.74% | 27.26% | 0.00 | |
| 31 Mar 2026 | 72.74% | 27.26% | 0.00 | |
| 31 Dec 2025 | 72.74% | 27.26% | 0.00 | |
| 30 Sep 2025 | 72.74% | 27.26% | – |
Major shareholders
Filings & events
News
No recent news coverage found.